Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
Novo Nordisk Strikes $2B Deal for Obesity Drug
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...
The Lancet5h
Increasing walking capacity in patients with peripheral artery disease
The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...
Is Ozempic a game-changer for insulin resistance? What you need to know
SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® ...
Managed Healthcare Executive5d
Novo Nordisk Extends Lowered Wegovy Price to Retail Pharmacies
Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...
Clinical Advisor5d
Could GLP-1RAs be a Novel Pharmacological Intervention for AUD?
Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.
Nasdaq3d
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
The trial has enrolled participants who are intended to be titrated on weekly semaglutide injections for 8 weeks (0.25 mg/week for 4 weeks followed by 0.5 mg/week for 4 weeks) before being ...